Compare RDW & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | DNTH |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.9B |
| IPO Year | N/A | N/A |
| Metric | RDW | DNTH |
|---|---|---|
| Price | $6.62 | $41.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $12.67 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 7.5M | 756.3K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $296,147,000.00 | $3,078,000.00 |
| Revenue This Year | $11.89 | N/A |
| Revenue Next Year | $43.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.87 | $13.37 |
| 52 Week High | $26.66 | $45.46 |
| Indicator | RDW | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 51.07 |
| Support Level | $5.11 | $40.98 |
| Resistance Level | $8.20 | $44.06 |
| Average True Range (ATR) | 0.58 | 1.74 |
| MACD | 0.21 | -0.52 |
| Stochastic Oscillator | 48.06 | 24.17 |
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.